Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Ingrezza (valbenazine) is indicated for the treatment of adults with tardive dyskinesia and for the treatment of chorea associated with Huntington’s disease.
• This summary is based on the review of four systematic review(s)/meta-analysis(es). ^[1-4]
• VMAT-2 inhibitors, including valbenazine, were more effective than placebo in achieving slight improvement in psychosis (RR = 1.77, 95% CI 1.03, 3.04), and were as effective as active comparators (RR = 1.05, 95% CI 0.6, 1.81).
• Valbenazine and deutetrabenazine both showed significant reductions in TD symptoms, with a ≥50% reduction in AIMS scores; valbenazine at 80 mg/day demonstrated robust results in both short-term and long-term studies, and deutetrabenazine was similarly effective at 12 mg twice daily.
• A specific trial in the Asian population confirmed significant improvements in AIMS scores for both valbenazine and deutetrabenazine, validating their effectiveness in this subgroup.
• Valbenazine and deutetrabenazine demonstrated favorable safety profiles with low rates of serious adverse events, without significant increases in QT prolongation, parkinsonism, suicidal ideation, or mortality observed.
• There is limited long-term safety data available for deutetrabenazine.
• There is no population types or subgroups information available in the reviewed studies.